Laquinimod

Drug Profile

Laquinimod

Alternative Names: ABR-215062; Laquinimod sodium; Nerventra; SAIK-MS; TV-5600

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Active Biotech
  • Developer Icahn School of Medicine at Mount Sinai; National University of Singapore; Ruhr-University Bochum; Tel Aviv University; Teva Pharmaceutical Industries; University College London; University of British Columbia
  • Class Quinolones; Small molecules
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Immunomodulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase II Crohn's disease; Huntington's disease
  • No development reported Lupus nephritis
  • Discontinued Systemic lupus erythematosus

Most Recent Events

  • 19 Sep 2016 The USFDA rescinds the Special Protocol Assessment for the phase III CONCERTO trial
  • 07 Oct 2015 Interim pharmacodynamics data from preclinical trials in Multiple sclerosis released by Teva
  • 18 Apr 2015 Laquinimod is still in phase III trials for relapsing remitting Multiple sclerosis in USA, Albania, Belarus, Bosnia-Herzegovina, Croatia, Chile, Georgia, Israel, Kazakhstan, Macedonia, Mexico, Moldova, Montenegro, Puerto Rico, Russia, Serbia, South Africa, South Korea, Turkey and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top